Here are four updates on GI companies from the past week.
According to Genome Web, Exact Sciences closed a revolving loan for $15 million and a non-revolving loan for $25.6 million, intended for their new headquarters project.
Senzime was awarded a CE Mark for its OnZurf probe, a tool for gastrointestinal tract surgical procedures.
The European Medicines Agency issued a positive opinion on Takeda and TiGenix's Cx601, a complex perianal fistulas treatment for adults with non-active/mildly active luminal Crohn's disease.